Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2380760 | 1.00 | SLC6A3 (0.43) | SLC6A3MEN1KMT2AHTTTSHR | |
| SCHEMBL2380756 | 1.00 | SLC6A3 (0.43) | SLC6A3MEN1KMT2AHTTTSHR | |
| SCHEMBL1829324 | 1.00 | SLC6A3 (0.43) | SLC6A3MEN1KMT2AHTTTSHR | |
| SCHEMBL8632556 | 0.85 | SLC6A3 (0.44) | SLC6A3MEN1KMT2AHTTTSHR | |
| SCHEMBL27328368 | 0.84 | MEN1 (0.35) | SLC6A3MEN1KMT2ATSHRHPGD | |
| SCHEMBL8979396 | 0.84 | ALDH1A1 (0.39) | SLC6A3MEN1KMT2AHTTTSHR | |
| SCHEMBL20695650 | 0.84 | HPGD (0.35) | SLC6A3MEN1KMT2ATSHRHPGD | |
| SCHEMBL9044976 | 0.84 | ALDH1A1 (0.39) | SLC6A3MEN1KMT2AHTTTSHR | |
| SCHEMBL19411314 | 0.84 | HPGD (0.35) | SLC6A3MEN1KMT2ATSHRHPGD | |
| SCHEMBL29198506 | 0.84 | ALDH1A1 (0.39) | SLC6A3MEN1KMT2AHTTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4695238-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4646416-A1 | CDK2 INHIBITORS | Blueprint Medicines Corporation (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250059151-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2025-02-20 | — | — | US | disclosed |
| US-20240383902-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-11-21 | — | — | US | disclosed |
| WO-2024216154-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-10-17 | — | — | WO | disclosed |
| US-12091395-B2 | Griseofulvin compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-09-17 | — | — | US | disclosed |
| US-20240239778-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2024-07-18 | — | — | US | disclosed |
| WO-2024148087-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| WO-2024148087-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20230159535-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2023-05-25 | — | — | US | disclosed |
| US-20230136988-A1 | GRISEOFULVIN COMPOUND | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-05-04 | — | — | US | disclosed |
| WO-2023278326-A1 | CDK2 INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-01-05 | — | — | WO | disclosed |
| US-20220411416-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-12-29 | — | — | US | disclosed |
| US-11472784-B2 | Griseofulvin compound | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-10-18 | — | — | US | disclosed |
| US-11407746-B2 | Griseofulvin compound and pharmaceutical use thereof | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-08-09 | — | — | US | disclosed |
| EP-4032883-A1 | GRISEOFULVIN COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2022-07-27 | — | — | EP | disclosed |
| CN-108779089-B | Griseofulvin compound | 第一三共株式会社 | 2022-04-29 | — | — | CN | disclosed |
| WO-2008068614-A2 | STEREOSELECTIVE SYNTHESIS OF 1-[6-ETHYL-1,2-DIHYDROXY-PROPYL)-PYRIDIN-3-YL]-3-[2-(4-METHYL-PIPERAZIN-1-YL)-BENZYL]-PYRROLIDIN-2-ONE | PFIZER PRODUCTS INC. (US) | 2008-06-12 | — | — | WO | disclosed |
| WO-2008068614-A2 | STEREOSELECTIVE SYNTHESIS OF 1-[6-ETHYL-1,2-DIHYDROXY-PROPYL)-PYRIDIN-3-YL]-3-[2-(4-METHYL-PIPERAZIN-1-YL)-BENZYL]-PYRROLIDIN-2-ONE | PFIZER PRODUCTS INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407746-B2 | Griseofulvin compound and pharmaceutical use thereof | ACBD3, GRN, NR3C1 | SLC6A3 1702/4885MEN1 654/4885KMT2A 4243/4885 |
| US-11472784-B2 | Griseofulvin compound | PTGS1, CYP11B1, GRIA1 | SLC6A3 2434/4885MEN1 2215/4885KMT2A 3933/4885 |
| US-20240239778-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | ACBD3, NR3C1, GRN | SLC6A3 1728/4885MEN1 654/4885KMT2A 4235/4885 |
| US-20230136988-A1 | GRISEOFULVIN COMPOUND | PTGS1, CYP11B1, GRIA1 | SLC6A3 2434/4885MEN1 2215/4885KMT2A 3933/4885 |
| US-20250059151-A1 | GRISEOFULVIN COMPOUND | PTGS1, CYP11B1, GRIA1 | SLC6A3 2434/4885MEN1 2215/4885KMT2A 3933/4885 |
| US-20240383902-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | SLC6A3 4207/4885MEN1 2312/4885KMT2A 571/4885 |
| US-12091395-B2 | Griseofulvin compound | PTGS1, CYP11B1, GRIA1 | SLC6A3 2434/4885MEN1 2215/4885KMT2A 3933/4885 |
| US-20230159535-A1 | CDK2 INHIBITORS | CDK2, CDK20, CDK2AP1 | SLC6A3 4207/4885MEN1 2312/4885KMT2A 571/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | SLC6A3 3236/4885MEN1 3022/4885KMT2A 1111/4885 |
| US-20220411416-A1 | GRISEOFULVIN COMPOUND AND PHARMACEUTICAL USE THEREOF | ACBD3, NR3C1, GRN | SLC6A3 1728/4885MEN1 654/4885KMT2A 4235/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.